stiripentol

Quote












not competition, it will just push epidiolex one notch down in the treatment protocol. If docs were going to use epidiolex as 3rd line, itll now be 4th. Stiripentol is used in EU and has good success. This may actually be an advantage for Zogenix since they did a DDI study and have data on interaction between stiripentol and their dravet product. docs might prefer to use zogenix product over epidiolex in patients that are on stiripentol, which i image will soon become almost every dravet patient. so, no, not necessarily competition, but definitely not a good thing.
 






anonymous said:
not competition, it will just push epidiolex one notch down in the treatment protocol. If docs were going to use epidiolex as 3rd line, itll now be 4th. Stiripentol is used in EU and has good success. This may actually be an advantage for Zogenix since they did a DDI study and have data on interaction between stiripentol and their dravet product. docs might prefer to use zogenix product over epidiolex in patients that are on stiripentol, which i image will soon become almost every dravet patient. so, no, not necessarily competition, but definitely not a good thing.
Click to expand...

SMH
 






Dravet is a very small market. Epidiolex is going to be used mainly for all epilepsies.

The reality is almost every Dravet patient is on a CBD already and will most likely witch out their CBD is not seizure free.

Epidiolex will have 10 times more use in LGS and will quickly rise in use in reftactory epilepsy.
 






“Used mainly for all epilepsies”. Epidiolex is going to be highly scrutinized by DEA/FDA....think only on-label use from payers perspective. Keep dreaming until the studies are done on a broad patient population and clinical efficacy is proven. Think P3 clinical trials. Maybe we can file for that from expanded access program. But that is a maybe?!?
 






























Top Bottom
Back
Quote